ValuEngine Lowers China Biologic Products (CBPO) to Strong Sell

China Biologic Products (NASDAQ:CBPO) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Wednesday.

Several other research firms have also recently issued reports on CBPO. Zacks Investment Research upgraded China Biologic Products from a “strong sell” rating to a “hold” rating in a research report on Tuesday. TheStreet cut China Biologic Products from a “b-” rating to a “c+” rating in a research report on Thursday, March 1st. Jefferies Group cut China Biologic Products from a “buy” rating to a “hold” rating in a research report on Monday. BidaskClub cut China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Finally, Deutsche Bank set a $105.00 target price on China Biologic Products and gave the stock a “buy” rating in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $101.00.

NASDAQ:CBPO opened at $78.71 on Wednesday. China Biologic Products has a 12-month low of $79.30 and a 12-month high of $82.11. The stock has a market cap of $2.65 billion, a P/E ratio of 15.90, a price-to-earnings-growth ratio of 1.18 and a beta of 1.47.

China Biologic Products (NASDAQ:CBPO) last released its earnings results on Friday, May 4th. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.22 by ($0.01). China Biologic Products had a return on equity of 17.29% and a net margin of 17.76%. The business had revenue of $112.50 million for the quarter, compared to analysts’ expectations of $118.25 million. During the same quarter in the prior year, the business posted $1.32 EPS. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts forecast that China Biologic Products will post 5.22 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Comgest Global Investors S.A.S. grew its holdings in China Biologic Products by 78.5% during the 4th quarter. Comgest Global Investors S.A.S. now owns 635,752 shares of the biopharmaceutical company’s stock valued at $50,078,000 after buying an additional 279,500 shares in the last quarter. First Trust Advisors LP grew its holdings in China Biologic Products by 60.8% during the 4th quarter. First Trust Advisors LP now owns 30,251 shares of the biopharmaceutical company’s stock valued at $2,383,000 after buying an additional 11,437 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in China Biologic Products during the 4th quarter valued at approximately $3,426,000. Wasatch Advisors Inc. grew its holdings in China Biologic Products by 66.1% during the 4th quarter. Wasatch Advisors Inc. now owns 228,373 shares of the biopharmaceutical company’s stock valued at $17,989,000 after buying an additional 90,891 shares in the last quarter. Finally, California Public Employees Retirement System grew its holdings in China Biologic Products by 9.4% during the 4th quarter. California Public Employees Retirement System now owns 48,964 shares of the biopharmaceutical company’s stock valued at $3,857,000 after buying an additional 4,207 shares in the last quarter. Institutional investors and hedge funds own 57.99% of the company’s stock.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit